Dysregulation of the immune system in mental disease, particularly complement component 4 (C4), which may be associated with schizophrenia, has been repeatedly observed. This study investigated the association between the level of serum component 4 and schizophrenia. Data were derived from a case-control association study of 40 unrelated adult patients with schizophrenia and 40 matched healthy controls. The component 4 level in serum was measured for comparative analysis by a component 4 enzyme-linked immunosorbent assay kit. Our findings suggest that the serum component 4 level is lower in patients with schizophrenia than in the controls, and the results apply to both males and females. Our results will lay an important foundation for establishing diagnostic methods and provide feasible and reliable evidence for the clinical treatment of schizophrenia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/YPG.0000000000000226 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aberrant Cortical Morphological Networks in First-Episode Schizophrenia.
Schizophr Bull
January 2025
Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou 510631, China.
Background And Hypothesis: Population-based morphological covariance networks are widely reported to be altered in schizophrenia. Individualized morphological brain network approaches have emerged recently. We hypothesize that individualized morphological brain networks are disrupted in schizophrenia.
View Article and Find Full Text PDFSchizoLMNet: a modified lightweight MobileNetV2- architecture for automated schizophrenia detection using EEG-derived spectrograms.
Phys Eng Sci Med
January 2025
Department of Electronics and Communication Engineering, Vishnu Institute of Technology, Bhimavaram, Andhra Pradesh, 534202, India.
Schizophrenia (SZ) is a chronic neuropsychiatric disorder characterized by disturbances in cognitive, perceptual, social, emotional, and behavioral functions. The conventional SZ diagnosis relies on subjective assessments of individuals by psychiatrists, which can result in bias, prolonged procedures, and potentially false diagnoses. This emphasizes the crucial need for early detection and treatment of SZ to provide timely support and minimize long-term impacts.
View Article and Find Full Text PDFEfficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel.
Neurol Ther
January 2025
Department of Psychiatry, Faculty of Medicine, Mental Health Unit, Virgen del Rocio University Hospital, Translational Psychiatry Group, IBiS-CSIC, CIBERSAM, University of Seville, Seville, Spain.
Introduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13-17 years).
View Article and Find Full Text PDFTransdiagnostic conceptualization of schizophrenia and autism spectrum disorder. An integrative framework of minimal self disturbance.
Neuropsychopharmacol Hung
December 2024
Pszichiátriai és Pszichoterápiás Klinika, Semmelweis Egyetem, Budapest.
Aims: Autism spectrum disorder and schizophrenia are traditionally viewed as distinct diagnostic categories. However, evidence increasingly suggests overlapping pathological functioning at various levels, starting from brain circuitry to behaviour. Notably, both disorders are characterized by anomalous minimal self-experience (altered body ownership and agency), which is a trait-like, phenomenological distortion.
View Article and Find Full Text PDFEfficacy and safety of iclepertin (BI 425809) with adjunctive computerized cognitive training in patients with schizophrenia.
Schizophr Res Cogn
June 2025
Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA.
Unlabelled: Despite significant patient burden, there are no approved pharmacotherapies to treat symptoms of cognitive impairment associated with schizophrenia (CIAS). This double-blind, placebo-controlled, parallel-group Phase II trial assessed the efficacy and safety of pharmacological augmentation of at-home computerized cognitive training (CCT) with iclepertin (BI 425809, a glycine transporter-1 inhibitor). Participants with schizophrenia (aged 18-50 years) on stable antipsychotic therapy, who were compliant with CCT during the run-in period, were enrolled.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!